- Home
- ARWR vs CPRI Comparison
ARWR vs CPRI Comparison
Compare ARWR & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- CPRI
- Stock Information
- Founded
- ARWR 2003
- CPRI 1981
- Country
- ARWR United States
- CPRI United Kingdom
- Employees
- ARWR N/A
- CPRI N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- CPRI Apparel
- Sector
- ARWR Health Care
- CPRI Consumer Discretionary
- Exchange
- ARWR Nasdaq
- CPRI Nasdaq
- Market Cap
- ARWR 2.5B
- CPRI 2.2B
- IPO Year
- ARWR 1993
- CPRI 2011
- Fundamental
- Price
- ARWR $36.64
- CPRI $21.14
- Analyst Decision
- ARWR Strong Buy
- CPRI Buy
- Analyst Count
- ARWR 8
- CPRI 11
- Target Price
- ARWR $47.75
- CPRI $23.64
- AVG Volume (30 Days)
- ARWR 2.4M
- CPRI 2.3M
- Earning Date
- ARWR 11-25-2025
- CPRI 11-06-2025
- Dividend Yield
- ARWR N/A
- CPRI N/A
- EPS Growth
- ARWR N/A
- CPRI N/A
- EPS
- ARWR N/A
- CPRI N/A
- Revenue
- ARWR $572,976,000.00
- CPRI $4,391,000,000.00
- Revenue This Year
- ARWR $21,421.26
- CPRI N/A
- Revenue Next Year
- ARWR N/A
- CPRI $3.75
- P/E Ratio
- ARWR N/A
- CPRI N/A
- Revenue Growth
- ARWR 2816.20
- CPRI N/A
- 52 Week Low
- ARWR $9.57
- CPRI $11.86
- 52 Week High
- ARWR $39.42
- CPRI $43.34
- Technical
- Relative Strength Index (RSI)
- ARWR 73.44
- CPRI 49.65
- Support Level
- ARWR $36.29
- CPRI $20.30
- Resistance Level
- ARWR $39.38
- CPRI $21.76
- Average True Range (ATR)
- ARWR 1.39
- CPRI 0.71
- MACD
- ARWR 0.06
- CPRI 0.03
- Stochastic Oscillator
- ARWR 69.44
- CPRI 55.73
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.